

Juan Francisco Sánchez Ávila

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4615472/publications.pdf>

Version: 2024-02-01

19
papers

919
citations

758635

12
h-index

794141

19
g-index

20
all docs

20
docs citations

20
times ranked

1341
citing authors

#	ARTICLE	IF	CITATIONS
1	Direct-Acting Antivirals in the Treatment of Hepatitis C Virus Recurrence after Liver Transplantation: Real-life Experience in a Mexican Cohort.. Archives of Medical Research, 2021, 52, 713-718.	1.5	3
2	Pocket ultrasound device as a complement to physical examination for ascites evaluation and guided paracentesis. Internal and Emergency Medicine, 2016, 11, 461-466.	1.0	31
3	Mexican Consensus on the Diagnosis and Management of Hepatitis C Infection. Annals of Hepatology, 2015, 14, S7-S48.	0.6	4
4	A Genetic Variant in the Interleukin 28B Gene As a Major Predictor for Sustained Virologic Response in Chronic Hepatitis C Virus Infection. Archives of Medical Research, 2015, 46, 448-453.	1.5	8
5	Diagnosis and treatment of hepatocellular carcinoma: An update. World Journal of Hepatology, 2015, 7, 362.	0.8	103
6	Consenso mexicano de diagnóstico y manejo del carcinoma hepatocelular. Revista De Gastroenterología De México, 2014, 79, 250-262.	0.4	13
7	Re-treatment with Highly Purified IFN α in Mexican Nonresponder Patients with Chronic Genotype 1 Hepatitis C. Archives of Medical Research, 2013, 44, 444-448.	1.5	1
8	Trends and projections of hepatitis C virus epidemiology in Latin America. Liver International, 2011, 31, 18-29.	1.9	115
9	IFN-stimulated Gene Expression Is a Useful Potential Molecular Marker of Response to Antiviral Treatment with Peg-IFN α 2b and Ribavirin in Patients with Hepatitis C Virus Genotype 1. Archives of Medical Research, 2011, 42, 28-33.	1.5	14
10	PPIs are not associated with a lower incidence of portal-hypertension-related bleeding in cirrhosis. World Journal of Gastroenterology, 2010, 16, 5869.	1.4	27
11	Prevalence of metabolic syndrome, obesity and diabetes type 2 in cryptogenic cirrhosis. World Journal of Gastroenterology, 2008, 14, 4771.	1.4	61
12	AST to platelet ratio index (APRI) for the noninvasive evaluation of liver fibrosis. Annals of Hepatology, 2008, 7, 350-357.	0.6	187
13	Non-Alcoholic Fatty-Liver Disease in Pediatric Populations. Journal of Pediatric Endocrinology and Metabolism, 2007, 20, 1059-73.	0.4	8
14	Cost efficacy and cost-benefit of treatment of hepatitis C. Annals of Hepatology, 2006, 5, S69-S73.	0.6	2
15	Efficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose-controlled study. Annals of Hepatology, 2006, 5, 281-288.	0.6	81
16	Insulin sensitizers in treatment of nonalcoholic fatty liver disease: Systematic review. World Journal of Gastroenterology, 2006, 12, 7826.	1.4	21
17	Etiology of Liver Cirrhosis in Mexico. Annals of Hepatology, 2004, 3, 30-33.	0.6	76
18	Extending combination therapy with peginterferon alfa-2b plus ribavirin for genotype 1 chronic hepatitis C late responders: A report of 9 cases. Hepatology, 2003, 37, 1226-1227.	3.6	58

#	ARTICLE	IF	CITATIONS
19	Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin. <i>Hepatology</i> , 2002, 35, 930-936.	3.6	106